Literature DB >> 32020518

Diabetes Mellitus and Acute Myocardial Infarction: Impact on Short and Long-Term Mortality.

Valentina Milazzo1, Nicola Cosentino1, Stefano Genovese1, Jeness Campodonico1, Mario Mazza1, Monica De Metrio1, Giancarlo Marenzi2.   

Abstract

Diabetes mellitus (DM) is an important risk factor for acute myocardial infarction (AMI) and a frequent co-morbidity in patients hospitalized with AMI, being present in about 30% of cases. Although current treatment of AMI has considerably improved survival in both patients with and without DM, the presence of DM still doubles the case fatality rate during both the acute phase of AMI and at long-term follow-up. This higher mortality risk of DM patients strongly indicates a particular need for better treatment options in these patients and suggests that intensive medical treatment, prolonged surveillance, and stringent control of other risk factors should be carefully pursued and maintained for as long as possible in them.In this review, we will focus on the close association between DM and in-hospital and long-term mortality in AMI patients. We will also aim at providing current evidence on the mechanisms underlying this association and on emerging therapeutic strategies, which may reduce the traditional mortality gap that still differentiates AMI patients with DM from those without.

Entities:  

Keywords:  Acute hyperglycemia; Acute myocardial infarction; Diabetes mellitus; In-hospital mortality; Long-term mortality; Non-ST-elevation myocardial infarction; Percutaneous coronary intervention; Pre-diabetes mellitus; ST-elevation myocardial infarction; Unknown diabetes mellitus

Year:  2021        PMID: 32020518     DOI: 10.1007/5584_2020_481

Source DB:  PubMed          Journal:  Adv Exp Med Biol        ISSN: 0065-2598            Impact factor:   2.622


  7 in total

Review 1.  Diabetes complications and extracellular vesicle therapy.

Authors:  Setareh Soltani; Kamran Mansouri; Shahram Parvaneh; Avnesh S Thakor; Flemming Pociot; Reza Yarani
Journal:  Rev Endocr Metab Disord       Date:  2021-10-14       Impact factor: 6.514

2.  Intervention by clinical pharmacists can improve blood glucose fluctuation in patients with diabetes and acute myocardial infarction: A propensity score-matched analysis.

Authors:  Fang-Hong Shi; Long Shen; Jiang Yue; Jing Ma; Zhi-Chun Gu; Hao Li; Hou-Wen Lin
Journal:  Pharmacol Res Perspect       Date:  2021-04

3.  Assessment of Trimetazidine Treatment in Acute Myocardial Infarction Patients Undergoing Percutaneous Coronary Intervention.

Authors:  Xiuying Tang; Jie Gong
Journal:  Cardiol Res Pract       Date:  2022-07-02       Impact factor: 1.990

Review 4.  Protein Quality Control at the Sarcomere: Titin Protection and Turnover and Implications for Disease Development.

Authors:  Sebastian Kötter; Martina Krüger
Journal:  Front Physiol       Date:  2022-06-30       Impact factor: 4.755

5.  Cardiac arrhythmias and mortality risk among patients with obstructive sleep apnea following admission for acute myocardial infarction or acute ischemic stroke.

Authors:  Kamleshun Ramphul; Petras Lohana; Renuka Verma; Nomesh Kumar; Yogeshwaree Ramphul; Arti Lohana; Shaheen Sombans; Stephanie Gonzalez Mejias; Komal Kumari
Journal:  Arch Med Sci Atheroscler Dis       Date:  2022-08-10

6.  Comparison of Clinical Outcomes after Non-ST-Segment and ST-Segment Elevation Myocardial Infarction in Diabetic and Nondiabetic Populations.

Authors:  Yong Hoon Kim; Ae-Young Her; Seung-Woon Rha; Cheol Ung Choi; Byoung Geol Choi; Ji Bak Kim; Soohyung Park; Dong Oh Kang; Ji Young Park; Sang-Ho Park; Myung Ho Jeong
Journal:  J Clin Med       Date:  2022-08-29       Impact factor: 4.964

7.  Prognostic impact of admission high-sensitivity C-reactive protein in acute myocardial infarction patients with and without diabetes mellitus.

Authors:  Claudia Lucci; Nicola Cosentino; Stefano Genovese; Jeness Campodonico; Valentina Milazzo; Monica De Metrio; Maurizio Rondinelli; Daniela Riggio; Maria Luisa Biondi; Mara Rubino; Katia Celentano; Alice Bonomi; Nicolò Capra; Fabrizio Veglia; Piergiuseppe Agostoni; Antonio L Bartorelli; Giancarlo Marenzi
Journal:  Cardiovasc Diabetol       Date:  2020-10-20       Impact factor: 9.951

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.